Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
Why Earnings Season Could Be Great for AbbVie (ABBV)
01:35pm, Thursday, 28'th Apr 2022 Zacks Investment Research
AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
How Gilead is positioning Veklury against COVID-19 antivirals like Paxlovid
01:02pm, Thursday, 28'th Apr 2022 MarketWatch
The company has an oral version of its COVID-19 drug Veklury in a clinical trial.
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
12:52pm, Thursday, 28'th Apr 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Moderna Seeks FDA Emergency Use Nod For COVID-19 Shot In Kids 2-6
Moderna Inc (NASDAQ: MRNA) submitt
Eli Lilly (LLY) Q1 Earnings and Revenues Top Estimates
11:35am, Thursday, 28'th Apr 2022 Zacks Investment Research
Lilly (LLY) delivered earnings and revenue surprises of 12.93% and 3.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
10:20am, Thursday, 28'th Apr 2022 Zacks Investment Research
Sector ETF report for FXH
3 Small-Cap Medical Stocks With Big Momentum
03:15pm, Wednesday, 27'th Apr 2022 The Motley Fool
Now is a good time to take a closer look at these stocks.
Will Biogen (BIIB) Succeed in Beating Q1 Earnings Estimates?
12:35pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Biogen's (BIIB) multiple sclerosis revenues have been declining since the past few quarters. It is unlikely that MS sales have improved in the first quarter.
Universal Health (UHS) Q1 Earnings Miss Mark, Tumble Y/Y
05:11pm, Tuesday, 26'th Apr 2022 Zacks Investment Research
Universal Health's (UHS) Q1 results reflect a steep expense level and lower admissions in its Behavioral Health Care Services segment, partially offset by revenue recognition.
Healthcare ETFs in Focus Ahead of Q1 Earnings
03:15pm, Tuesday, 26'th Apr 2022 Zacks Investment Research
The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfo
Will Merck (MRK) Beat Expectations This Earnings Season?
01:31pm, Tuesday, 26'th Apr 2022 Zacks Investment Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and the new COVID-19 antiviral pill, molnupiravir when the company reports Q1 earnings.
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
09:45pm, Monday, 25'th Apr 2022 Zacks Investment Research
AbbVie (ABBV) closed at $156.30 in the latest trading session, marking a +0.85% move from the prior day.
Analyst Ratings for AbbVie
06:10pm, Monday, 25'th Apr 2022 Benzinga
Analysts have provided the following ratings for AbbVie (NYSE:ABBV) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
2
4
0
0
Last 30D
0
3 Warren Buffett Dividend Stocks You Can Buy Right Now
09:52am, Monday, 25'th Apr 2022 The Motley Fool
They're not good picks just because of their dividends.
These Dividend Stocks Are Trouncing the Market -- Are They Still Buys?
09:52am, Sunday, 24'th Apr 2022 The Motley Fool
Investors don't like these stocks only because of their dividends.
3 Dividend Growth Titans to Increase Your Passive Income
09:00am, Sunday, 24'th Apr 2022 The Motley Fool
There's nothing quite like a growing dividend to help you cover your costs when inflation rears its ugly head.
